Peptide Injection Technique: Subcutaneous, Intramuscular, Intranasal & Sublingual

Proper administration technique is essential for consistent peptide delivery, research reproducibility, and safety. This guide provides step-by-step instructions for the four most common routes used in peptide research: subcutaneous, intramuscular, intranasal, and sublingual.

For a broader overview of route bioavailability and peptide-specific route selection, see the Peptide Administration Guide.

Subcutaneous (SC) Injection

Subcutaneous injection is the most widely used route for research peptides. It delivers the peptide into the adipose (fat) tissue layer beneath the skin, where it is absorbed gradually into systemic circulation. Most peptides studied in research contexts — including BPC-157, TB-500, Ipamorelin, and Sermorelin — are commonly administered via this route.

Step-by-Step Subcutaneous Technique

1. Prepare your workspace

Gather all materials on a clean, flat surface: reconstituted peptide vial, insulin syringe (29G or 30G recommended), alcohol swabs, cotton balls or gauze, and a sharps container. Ensure adequate lighting.

2. Wash hands thoroughly

Use soap and warm water for at least 20 seconds. Dry with a clean towel. This is the single most important step in preventing infection (Boyce & Pittet, 2002).

3. Prepare the syringe

• Wipe the vial stopper with an alcohol swab and let it air dry
• Pull back the plunger to fill the syringe with air equal to the volume you plan to draw
• Insert the needle through the vial stopper and inject the air (this equalizes pressure)
• Invert the vial and draw the peptide solution slowly to the desired volume
• Tap the syringe barrel to move any air bubbles to the top, then gently push the plunger to expel them
• Confirm the correct volume

4. Clean the injection site

Swab the chosen injection site with an alcohol pad using a circular motion from center outward. Allow the alcohol to dry completely — injecting through wet alcohol causes stinging and can carry alcohol into the tissue.

5. Pinch the skin

Using your non-dominant hand, pinch a 1-2 inch fold of skin and subcutaneous tissue between your thumb and forefinger. This lifts the adipose layer away from the underlying muscle, ensuring the injection remains subcutaneous.

6. Insert the needle

• For 8 mm needles: Insert at a 45-degree angle relative to the skin surface
• For 6 mm needles or in areas with ample subcutaneous tissue: Insert at a 90-degree angle
• Use a smooth, swift motion — hesitation increases discomfort

7. Aspirate (optional)

Some protocols recommend pulling back slightly on the plunger to check for blood return, which would indicate accidental vascular puncture. While current CDC guidelines consider aspiration unnecessary for subcutaneous injections, it remains common practice in many research settings.

8. Inject slowly

Depress the plunger slowly and steadily over 5-10 seconds. Rapid injection forces fluid into the tissue too quickly, causing pressure-related discomfort and potentially affecting local absorption.

9. Withdraw and apply pressure

• Remove the needle at the same angle used for insertion
• Release the skin pinch
• Apply gentle pressure to the site with a clean cotton ball or gauze for 10-15 seconds
• Do not rub — rubbing can disperse the peptide into surrounding tissue unevenly or cause bruising

Subcutaneous Injection Sites

Rotate injection sites systematically, maintaining at least 1 inch (2.5 cm) between consecutive injection points to prevent lipohypertrophy and maintain consistent absorption.

Intramuscular (IM) Injection

Some peptides are administered intramuscularly for faster absorption or when targeting muscle tissue directly. Peptides such as CJC-1295 and certain growth hormone-releasing peptides may use the IM route in some research protocols.

Key Differences from Subcutaneous

• Needle gauge: 25G-27G is typical for IM (larger than SC)
• Needle length: 1-1.5 inches (25-38 mm) to reach muscle tissue
• Injection angle: 90 degrees (perpendicular to the skin)
• No skin pinch — instead, the skin is pulled taut or the muscle is relaxed
• Faster absorption — muscle tissue has greater blood flow than subcutaneous fat

Intramuscular Technique

1. Select and prepare the site — Clean with an alcohol swab
2. Position appropriately — The muscle should be relaxed; tensing the muscle increases pain and can impede proper needle insertion
3. Spread the skin taut using the Z-track method: pull the skin to one side with your non-dominant hand before inserting the needle. This prevents solution from tracking back along the needle path after withdrawal
4. Insert at 90 degrees with a firm, controlled motion
5. Aspirate — For IM injections, aspiration (pulling back the plunger for 5-10 seconds to check for blood) is more commonly practiced than with SC injections, particularly for gluteal injections near the superior gluteal artery
6. Inject steadily — Deliver the solution over 10-15 seconds
7. Withdraw and release — Remove the needle and release the Z-track skin displacement, which seals the injection pathway
8. Apply pressure — Hold gauze over the site; do not rub

Intramuscular Injection Sites

• Deltoid muscle — Used for small volumes (up to 1 mL). Located on the lateral aspect of the upper arm, approximately 2-3 finger widths below the acromion process. Easily accessible but limited in volume capacity
• Vastus lateralis (lateral thigh) — Accommodates larger volumes (up to 2 mL). Located on the outer middle third of the thigh. Well-suited for self-administration
• Ventrogluteal (hip) — Accommodates the largest volumes (up to 3 mL). Located by placing the heel of the hand on the greater trochanter with fingers pointing toward the anterior iliac crest. Preferred over dorsogluteal due to absence of major nerves and blood vessels
• Dorsogluteal (upper outer buttock) — Historically common but carries risk of sciatic nerve injury; ventrogluteal is now preferred in most guidelines (Cocoman & Murray, 2008)

Intranasal Administration

Intranasal delivery provides a non-invasive route with potential for direct nose-to-brain transport via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier to some degree (Dhuria et al., 2010). This route is used for specific peptides with CNS targets.

Peptides Commonly Administered Intranasally

• Semax — A synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects; available in intranasal formulations in some regions
• Selank — A synthetic tuftsin analog with anxiolytic properties; developed as a nasal spray
• PT-141 (Bremelanotide) — While primarily subcutaneous, early research explored intranasal delivery; nasal formulations have been studied for sexual dysfunction research

Intranasal Technique

1. Clear nasal passages

Gently blow nose to remove mucus. Do not use immediately after nasal decongestant sprays, as vasoconstriction reduces mucosal absorption.

2. Prime the spray device

If using a metered-dose nasal spray for the first time or after extended storage, prime by pumping several times until a fine mist is produced, directing it away from the face.

3. Proper positioning

• Tilt the head slightly forward (chin toward chest)
• Insert the spray tip just inside the nostril (about 1 cm) — do not insert deeply
• Angle the tip slightly outward, toward the ear on the same side, to direct the spray toward the turbinates rather than the septum

4. Administer the spray

• Close the opposite nostril with a finger
• Breathe in gently through the nose while actuating the spray — a gentle sniff, not a forceful inhalation (which would pull the solution past the nasal cavity into the throat)
• Hold breath for a few seconds after spraying

5. Alternate nostrils

For multi-spray doses, alternate between left and right nostrils. This distributes the peptide across a larger mucosal surface area and reduces local irritation.

6. Avoid sneezing or blowing nose

Wait at least 10-15 minutes after administration before blowing the nose or sneezing if possible, to maximize mucosal contact time.

Intranasal Safety Considerations

• Mucosal irritation — Repeated intranasal use can cause dryness, irritation, or minor epistaxis (nosebleeds). Monitor nasal tissue integrity
• Dose variability — Nasal congestion, mucosal condition, and technique consistency all affect absorption; intranasal bioavailability is inherently more variable than injection routes
• Swallowed fraction — A portion of the administered dose will drain into the pharynx and be swallowed. Peptides are typically degraded in the GI tract, so this fraction is largely lost

Sublingual Administration

Sublingual delivery places the peptide under the tongue, where it can be absorbed through the highly vascularized sublingual mucosa directly into systemic circulation, bypassing first-pass hepatic metabolism.

Peptides Studied via Sublingual Route

• Some bioregulator peptides (e.g., Epithalon, small Khavinson peptides) — Their very small size (2-4 amino acids) allows limited mucosal absorption
• BPC-157 — Has been studied in oral and sublingual formats; its gastric stability is unusual among peptides (Sikiric et al., 2018)
• Small peptides and peptidomimetics — Compounds under approximately 1,000 Da may achieve meaningful sublingual absorption

Sublingual Technique

1. Prepare the dose

Using a syringe (without needle) or calibrated dropper, measure the prescribed volume of peptide solution.

2. Place under the tongue

Lift the tongue and deposit the solution into the sublingual space — the area beneath the tongue between the frenulum and the floor of the mouth. This region has thin, non-keratinized epithelium and dense capillary networks.

3. Hold in place

Keep the solution under the tongue for 60-90 seconds without swallowing. This contact time allows absorption through the sublingual mucosa. Longer hold times (up to 2 minutes) may improve absorption for some compounds.

4. Avoid eating and drinking

Do not eat, drink, or rinse the mouth for at least 15 minutes after sublingual administration. Food and liquid can dilute or wash away the peptide before complete absorption.

5. Minimize saliva production

Excessive saliva will dilute the peptide and prompt swallowing. Avoid placing the solution too far back on the tongue, which triggers the swallowing reflex.

Sublingual Limitations

• Bioavailability is generally low — Most peptides larger than ~10 amino acids do not achieve meaningful sublingual absorption due to molecular size and hydrophilicity
• Dose variability — Absorption depends on mucosal integrity, saliva flow, pH, and individual anatomy
• Enzymatic degradation — Salivary proteases can degrade peptides during the holding period
• Volume limitations — The sublingual space accommodates approximately 1 mL of fluid; larger volumes will spread beyond the absorption zone or be swallowed

General Safety Considerations

Across All Routes

• Aseptic technique is non-negotiable — Contamination introduces infection risk and can degrade peptides
• Single-use syringes only — Never reuse needles or syringes. Dispose of sharps immediately in a puncture-resistant container
• Record keeping — Document the date, time, peptide, dose, route, lot number, and injection site for every administration
• Adverse reaction monitoring — Watch for signs of infection (redness, swelling, warmth, pain at injection site), allergic reaction (hives, swelling, difficulty breathing), or systemic effects
• Storage compliance — Only use properly stored, non-expired peptides reconstituted with appropriate diluent. See the Peptide Storage Guide and Bacteriostatic Water Guide

When to Discontinue

• Persistent redness, swelling, or induration at injection sites that does not resolve within 48 hours
• Signs of systemic allergic reaction
• Any unexpected adverse effects
• Peptide solution that appears cloudy, discolored, or contains visible particles